Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Burkitt Lymphoma 28Leukemia, Biphenotypic, Acute 16Leukemia, Myeloid, Acute 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia 10Myelodysplastic Syndromes 9Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 6Leukemia, Myeloid, Accelerated Phase 6Blast Crisis 6Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 5Graft vs Host Disease 5Osteosarcoma 4Medulloblastoma 4Down Syndrome 4Urinary Bladder Neoplasms 3Recurrence 3Primary Myelofibrosis 3Neoplasm Metastasis 3Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Juvenile 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Thrombocythemia, Essential 2Rhabdoid Tumor 2Polycythemia Vera 2

Interventions

Magnetic Resonance Spectroscopy 8Specimen Handling 7Biopsy 6X-Rays 5Phantoms, Imaging 5Temozolomide 4Nuclear Medicine Department, Hospital 4Nivolumab 4Carboplatin 4selpercatinib 3larotrectinib 3Topotecan 3Etoposide 3Cyclophosphamide 3Cisplatin 3Automobiles 3tazemetostat 2pembrolizumab 2erdafitinib 2entrectinib 2ensartinib 2cabozantinib 2Vincristine 2Surveys and Questionnaires 2Radiotherapy 2Radiosurgery 2Radiation 2Positron-Emission Tomography 2Paclitaxel 2ONC206 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Methotrexate × 1 year × Clear all
NCT00602667 2026-05-19

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
293 enrolled 89 charts
CNS

Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor

NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

The University of Texas Health Science Center, Houston

Phase 1 Withdrawn
CNS

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡